The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate

The Effect of GLP-1 on Postprandial Glucagon Secretion During Prolonged and Intermittent Stimulation of the GLP-1 Receptor Independent of The Gastric Emptying Rate. A Randomized, Open-label Study in People With Type 1 Diabetes

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02584582

Acronym

ALFA-1

Enrollment

Registered

2015-10-22

Start date

2015-07-31

Completion date

Unknown

Last updated

2015-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

Glucagon, Glukagon-like peptide-1 (GLP-1), GLP-1 receptor agonist (GLP-1RA), Incretins

Brief summary

Aim: To investigate the glucagonostatic effect of glucagon-like peptide-1 (GLP-1) independent of the gastric emptying rate.

Detailed description

Aim: To investigate the glucagonostatic effects of glucagon-like peptide-1 (GLP-1) during prolonged and intermittent stimulation of the GLP-1 receptor independent of the gastric emptying rate. Glucagon concentrations will be measured following a liquid meal administered in duodenum at baseline and after exenatide, and liraglutide treatment.

Interventions

DRUGLiraglutide

DRUGExenatide

PROCEDURELiquid meal test

OTHERNo drug (Baseline day)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 1 Diabetes * \>18 years * No residual beta-cell function (stimulated C-peptide \< 60 pmol)

Exclusion criteria

* Pancreatitis * gastroparesis * history of alcohol and/or drug abuse * pregnancy and lactation * other medical or psychological condition that made the patient unsuitable for study participation according to the investigators´ assessment * contraindications to gastroscopy * cancer (unless in complete remission \> five years)

Design outcomes

Primary

Measure	Time frame	Description
Glucagon concentration (postprandial)	4 hours	glucagon area under the curve (AUC) (0-240 minutes) and baseline to peak increments will be calculated

Secondary

Measure	Time frame	Description
glucagon-like peptide-1 (GLP-1)	4 hours	GLP-1 AUC (0-240 minutes) and baseline to peak increments will be calculated
glucagon-like peptide-2 (GLP-2)	4 hours	GLP-2 AUC (0-240 minutes) and baseline to peak increments will be calculated
glucose-dependent insulinotropic polypeptide (GIP)	4 hours	GIP AUC (0-240 minutes) and baseline to peak increments will be calculated
Cholecystokinin (CCK)	4 hours	CCKAUC (0-240 minutes) and baseline to peak increments will be calculated
Peptide YY (PYY)	4 hours	PYY AUC (0-240 minutes) and baseline to peak increments will be calculated
Postprandial glucose concentrations	4 hours	glucose AUC (0-240 minutes) and baseline to peak increments will be calculated
Gastrin	4 hours	Gastrin AUC (0-240 minutes) and baseline to peak increments will be calculated
Oxyntomodulin	4 hours	Oxyntomodulin AUC (0-240 minutes) and baseline to peak increments will be calculated
Free fatty acids (FFA)	4 hours	FFA AUC (0-240 minutes) and baseline to peak increments will be calculated
triacylglycerol (TAG)	4 hours	TAG AUC (0-240 minutes) and baseline to peak increments will be calculated
Ghrelin	4 hours	Ghrelin AUC (0-240 minutes) and baseline to peak increments will be calculated

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026